Intercept Pharma (NASDAQ:ICPT) Receives Downgrade From Raymond James. Will Other Analysts Follow Suit?

October 2, 2018 - By Adrian Mccoy

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Logo

Investors sentiment increased to 1.27 in 2018 Q2. Its up 0.12, from 1.15 in 2018Q1. It is positive, as 15 investors sold Intercept Pharmaceuticals, Inc. shares while 40 reduced holdings. 25 funds opened positions while 45 raised stakes. 19.65 million shares or 4.20% more from 18.85 million shares in 2018Q1 were reported.

Amer reported 0% of its portfolio in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Citigroup owns 1,072 shares. 89,885 are owned by National Bank & Trust Of Mellon Corporation. Opus Point Ptnrs Limited Liability Corporation has invested 0.73% in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT). Great West Life Assurance Can has 0% invested in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for 1,989 shares. Us Bank De stated it has 1,775 shares or 0% of all its holdings. Moreover, Huntington Commercial Bank has 0% invested in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) for 50 shares. Lpl Fincl Ltd Liability holds 76,038 shares or 0.02% of its portfolio. Ameritas Invest Prtn Inc has 1,808 shares. Credit Suisse Ag, Switzerland-based fund reported 122,561 shares. Amalgamated National Bank & Trust accumulated 0.01% or 3,337 shares. Ubs Asset Americas holds 0% or 10,396 shares. Daiwa Secs Group Inc accumulated 0% or 139 shares. Fifth Third Bank & Trust holds 0% or 736 shares. Ameriprise holds 0% or 42,401 shares in its portfolio.

Intercept Pharma (NASDAQ:ICPT) Receives a Downgrade

In an analyst note issued to clients and investors on Tuesday, 2 October, Raymond James downgraded shares of Intercept Pharma (NASDAQ:ICPT) to a lower Outperform rating from the previous Strong Buy rating.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Ratings Coverage

Among 7 analysts covering Intercept Pharmaceuticals (NASDAQ:ICPT), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Intercept Pharmaceuticals has $217 highest and $95 lowest target. $171’s average target is 42.44% above currents $120.05 stock price. Intercept Pharmaceuticals had 8 analyst reports since April 17, 2018 according to SRatingsIntel. On Monday, August 6 the stock rating was upgraded by Goldman Sachs to “Buy”. The stock has “Overweight” rating by Cantor Fitzgerald on Monday, October 1. The stock has “Sector Perform” rating by RBC Capital Markets on Wednesday, August 15. Wedbush maintained Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) rating on Monday, August 6. Wedbush has “Outperform” rating and $217 target. The firm has “Hold” rating given on Friday, August 3 by Laidlaw. The rating was maintained by Wedbush on Tuesday, April 17 with “Outperform”.

The stock decreased 5.07% or $6.41 during the last trading session, reaching $120.05. About 343,427 shares traded. Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has risen 19.09% since October 2, 2017 and is uptrending. It has outperformed by 3.47% the S&P500.

Analysts await Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) to report earnings on November, 7. They expect $-2.58 earnings per share, up 10.73 % or $0.31 from last year’s $-2.89 per share. After $-2.58 actual earnings per share reported by Intercept Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The company has market cap of $3.55 billion. The Company’s lead product candidate is obeticholic acid , a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). It currently has negative earnings. The firm is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia.

More notable recent Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) news were published by: Streetinsider.com which released: “Cantor Fitzgerald Transfers Coverage on Intercept Pharmaceuticals (ICPT), Upgrades to Overweight” on September 30, 2018, also Seekingalpha.com with their article: “Premarket analyst action – healthcare” published on October 02, 2018, Benzinga.com published: “10 Biggest Price Target Changes For Tuesday” on October 02, 2018. More interesting news about Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) were released by: Streetinsider.com and their article: “Raymond James Downgrades Intercept Pharmaceuticals (ICPT) to Outperform” published on October 02, 2018 as well as Investorplace.com‘s news article titled: “5 Biotech Stocks to Play the Sector’s Next Big Trend: NASH” with publication date: September 26, 2018.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>